Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AnsellASX:ANN +0.07%74 3-Year FCF Growth Rate is 36.30% as of Jun. 2026, which is 585% above its 10-year median of 5.30. GuruFocus rates ASX:ANN with a GF Score™ of 74/100 and a GF Value™ of A$31.70 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 585 Medical Devices & Instruments companies, Ansell ranks better than 70.43% on this metric.
During the past 12 months, Ansell's average Free Cash Flow per Share Growth Rate was 88.20% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 36.30% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 23.10% per year.
During the past 10 years, the average Free Cash Flow per Share Growth Rate was 6.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Ansell was 79.90% per year. The lowest was -18.80% per year. And the median was 5.30% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Ansell 3-Year FCF Growth Rate Related Terms
ASX:ANN vs ISRG, BDX, RMD: 3-Year FCF Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Ansell's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ansell 3-Year FCF Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ansell's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Ansell's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 36.30% mean?
Ansell (ASX:ANN) has a 3-Year FCF Growth Rate of 36.30% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Ansell and its competitors. This is 585% above median its historical median of 5.30. According to the industry distribution chart, Ansell ranks #173 out of 585 companies in the Medical Devices & Instruments industry, placing it in the top 29.6%.
Is Ansell's 3-Year FCF Growth Rate too high?
Ansell's current 3-Year FCF Growth Rate of 36.30% is 585% above median its 10-year median of 5.30. The Medical Devices & Instruments industry median 3-Year FCF Growth Rate is 18.00. Ansell's value of 36.30% is 101.7% above this industry median. Based on the distribution chart, Ansell ranks #173 out of 585 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Ansell has a GF Score™ of 74/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ansell's 3-Year FCF Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ansell ranks #173 out of 585 companies for 3-Year FCF Growth Rate. This puts Ansell in the upper half of its industry. The industry median 3-Year FCF Growth Rate is 18.00. Ansell's value of 36.30% is 101.7% above this benchmark. While the company's 10-year median is 5.30 vs. the industry median of 18.00, Ansell has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Devices & Instruments company?
The median 3-Year FCF Growth Rate among Medical Devices & Instruments companies is 18.00, based on 585 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ansell's current 3-Year FCF Growth Rate of 36.30% is 101.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Ansell and its competitors. For the Medical Devices & Instruments industry, the median 3-Year FCF Growth Rate is 18.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ansell's current 3-Year FCF Growth Rate is 36.30%, which is 585% above median its own 10-year median of 5.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ansell stock overvalued right now?
Based on GuruFocus' analysis, Ansell (ASX:ANN) is currently considered Modestly Overvalued. The stock's GF Value™ is A$31.70, compared to a current price of A$41.34 — trading 30.4% above its estimated fair value. The current 3-Year FCF Growth Rate is 36.30%, which is 585% above median its 10-year median of 5.30 and 101.7% above the Medical Devices & Instruments industry median of 18.00. Ansell's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Ansell (ASX:ANN), the current 3-Year FCF Growth Rate is 36.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ansell (ASX:ANN) Overvalued in 2026?
Based on GuruFocus' analysis, Ansell stock appears to be overvalued.
The current stock price of A$41.34 is trading 30.4% above its estimated GF Value™ of A$31.70.
GuruFocus considers Ansell to be Modestly Overvalued.
Key valuation signals for ASX:ANN:
3-Year FCF Growth Rate: 36.30% (585% above median its 10-year median of 5.30)
GF Value™: A$31.70 vs. price of A$41.34 (30.4% above fair value)
Industry Position: 101.7% above the Medical Devices & Instruments median (#173 of 585)
No single metric tells the full story. See the ASX:ANN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ansell is a leading supplier of protective gloves for use in healthcare and industrial settings, earning approximately 55% of revenue and operating profit from the healthcare segment and the remainder from the industrial segment. The company holds a large number of patents, and the majority of sales come from its key branded product ranges. Ansell has a global manufacturing and distribution footprint and distributes via key partners as well as directly. Largest sales regions are North America and Europe, Middle East, and Africa. Asia-Pacific and Latin America, combined, are about one-fourth of sales.
74GF Score
Get the complete analysis for ASX:ANN
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ANN has been successfully added to your 
